Share

February 19, 2013; 80 (8) Article

Migraine prevention with a supraorbital transcutaneous stimulator

A randomized controlled trial

Jean Schoenen, Bart Vandersmissen, Sandrine Jeangette, Luc Herroelen, Michel Vandenheede, Pascale Gérard, Delphine Magis
First published February 6, 2013, DOI: https://doi.org/10.1212/WNL.0b013e3182825055
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1627

Share

This article has a correction. Please see:

Article Information

vol. 80 no. 8 697-704
DOI: 
https://doi.org/10.1212/WNL.0b013e3182825055
PubMed: 
23390177
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received April 23, 2012
  • Accepted October 4, 2012
  • First Published February 6, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Jean Schoenen, MD, PhD,
    2. Bart Vandersmissen, MD,
    3. Sandrine Jeangette, MD,
    4. Luc Herroelen, MD,
    5. Michel Vandenheede, MD,
    6. Pascale Gérard, Phy and
    7. Delphine Magis, MD, PhD
  1. Jean Schoenen, MD, PhD,
    2. Scientific Advisory Boards:

    1. - St Jude Medical USA, - Allergan USA - ATI USA

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. ATI Redwood Cal USA - travel expenses to congress

    Editorial Boards:

    1. - Acta Neurologica Belgica, Editor-in-chief, 2009-ongoing- Cephalalgia, Associate Editor, 2005-ongoing- Journal of Head and Pain, Editorial Advisory Board Member, 2008-ongoing

    Patents:

    1. Use of thioctic acid as a preventive treatment in migraine

    Publishing Royalties:

    1. Wall & Melzack's Textbook of Pain. Elsevier. 2001- Handbook of Pain Management. Elsevier. 2009- Wall & Melzack's Textbook of Pain. Elsevier. 2010- Comorbidity in Migraine. Wiley & Blackwell. 2011- Multidisciplinary Management of Migraine. Jones & Bartlett Learning. 2012

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. ATI Redwood Cal USA

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. - Medtronic USA - Cyberonics USA.

    Research Support, Government Entities:

    1. National Fund for Scientific Research - Belgium. Research Convention 3.4650.09, 2009-2012

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Bart Vandersmissen, MD,
    3. Scientific Advisory Boards:

    1. (1) Allergan

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)acta neurologica belgica, associate editor, since 2012

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sandrine Jeangette, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Invited by Janssen-Cilag to attend the “migraine trust” annual meeting in London-UK: Travel expenses and accommodation.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Luc Herroelen, MD,
    5. Scientific Advisory Boards:

    1. Served on the scientific advisory board for Allergan (2010-2012).

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Michel Vandenheede, MD,
    6. Scientific Advisory Boards:

    1. (1) Allergan - USA

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Pascale Gérard, Phy and
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Delphine Magis, MD, PhD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Headache Research Unit (J.S., P.G., D.M.), Department of Neurology & GIGA–Neurosciences, Liège University, Citadelle Hospital, Liege; Department of Neurology (B.V.), CHU Erasme, University of Brussels & Clinique de l'Europe, Brussels; Department of Neurology (S.J.), CHU Charleroi, Charleroi; Department of Neurology (L.H.), AZ Gasthuisberg, Catholic University of Leuven, Leuven; and CHC Espérance Liège (M.V.), Montegnee, Belgium.
  1. Correspondence to Dr. Schoenen: jschoenen{at}ulg.ac.be
View Full Text

Article usage

Article usage: February 2013 to November 2019

AbstractFullPdfSource
Feb 2013670862243Highwire
Mar 201317604373Highwire
Apr 201312582650Highwire
May 20136522031Highwire
Jun 20134891320Highwire
Jul 20133721221Highwire
Aug 20133161216Highwire
Sep 20134082132Highwire
Oct 20134261318Highwire
Nov 2013387815Highwire
Dec 201330288Highwire
Jan 20144301215Highwire
Feb 20143601213Highwire
Mar 20143567103160Highwire
Apr 201418653463Highwire
May 201410773534Highwire
Jun 20147632129Highwire
Jul 20149372032Highwire
Aug 20145841732Highwire
Sep 20146111119Highwire
Oct 20146541016Highwire
Nov 20144981724Highwire
Dec 2014506812Highwire
Jan 20155971623Highwire
Feb 2015492815Highwire
Mar 20157541314Highwire
Apr 2015608719Highwire
May 201564856Highwire
Jun 20155592022Highwire
Jul 201568759Highwire
Aug 20151456915Highwire
Sep 20151340914Highwire
Oct 201514381312Highwire
Nov 20151332818Highwire
Dec 201514261117Highwire
Jan 201613681214Highwire
Feb 2016132087Highwire
Mar 201613381014Highwire
Apr 20161257811Highwire
May 20161365717Highwire
Jun 20161396511Highwire
Jul 20161687511Highwire
Aug 201613581114Highwire
Sep 20161309815Highwire
Oct 20161350811Highwire
Nov 2016132928Highwire
Dec 20161408713Highwire
Jan 20171346710Highwire
Feb 2017130699Highwire
Mar 20171474712Highwire
Apr 20171300710Highwire
May 2017121555Highwire
Jun 20171209410Highwire
Jul 20171254310Highwire
Aug 2017114052Highwire
Sep 20171120921Highwire
Oct 201711461014Highwire
Nov 201785868Highwire
Dec 201789996Highwire
Jan 20181308188Highwire
Feb 20181218246Highwire
Mar 201811551814Highwire
Apr 20189611814Highwire
May 2018917115Highwire
Jun 201891485Highwire
Jul 2018101862Highwire
Aug 20181105136Highwire
Sep 20181240177Highwire
Oct 201811321810Highwire
Nov 201811942013Highwire
Dec 20181299199Highwire
Jan 201911901510Highwire
Feb 2019959107Highwire
Mar 20198861117Highwire
Apr 20198491212Highwire
May 2019502109Highwire
Jun 2019308148Highwire
Jul 2019267167Highwire
Aug 20191811110Highwire
Sep 2019202149Highwire
Oct 20192262111Highwire
Nov 201921655Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me